Jun. 14 at 7:28 PM
$RANI This is one of the most Undervalued small bio-tech Companies that I profile (IMO). RaniPill® capsule is a swallowed pill designed to navigate the stomach and deliver biologic drugs directly into the intestinal wall with high bioavailability. I have spoken about this specific to GLP1/2 in the past, but the technology is an injectable alternative potentially to ALL biologics. RT-114 (GLP1/2) serves as a good case study in an incredibly strong market for the efficacy of the Ranipill and their drug candidate. The Chugai deal (licensing for hemophilia product) has more than
$1.0B in potential value alone; it included up-front cash and structured milestone payments. Multi-billion dollar potential across several different verticals with a market cap of
$94M.
$43M in Cash against
$16M in Total Liabilities with TTM burn rate of
$17M. High risk, High reward, multiplier upside possible (IMO).
